You are here
Poor stock management contributed to theft of medicines purchased with Global Fund grants to C.A.R., OIG says
There were ongoing leakages of ACTs over a 17-month period
Political instability, decreasing resources and a resurgent malaria epidemic: A challenging environment for Global Fund grants in Burundi
Malaria incidence doubled between 2014 and 2016
Ukraine starts transition away from Global Fund support without a detailed transition plan, OIG says
Audit gives Ukraine a mixed report card
Ambitious national targets for getting people on treatment often not reflected in grant performance frameworks, GAC says
The reason? “Limitations of budgets in the 2017-2019 allocations period”
GAC calls for urgent inter-agency discussions, with donor governments included
In its report to the Board on the third batch of grants it recommended for approval, the Grant Approvals Committee (GAC) said that it was very concerned that national programs have ambitious goals to continue scaling up antiretroviral therapy (ART), with the aim of achieving the 90-90-90 targets or even treating all patients diagnosed with HIV – but that these goals are not necessarily reflected in performance frameworks because of “limitation
Twenty funding requests yielded 32 grants
Audit of Global Fund grants to Mali reveals significant progress in financial management and quality of services
However, there are problems with drug expiries, stock-outs and delays in the supply chain
New government in Macedonia budgets for ARVs and prevention services to KAPs, as Global Fund support comes to an end
Decision hailed as a “very important step in ensuring the sustainability of HIV services”
MOH will be required to establish a long-term mechanism for funding CSOs
On 5 September, the recently elected government of the Republic of Macedonia ordered the Ministry of Health to allocate 103 million Macedonian denars (approximately € 1,674,000) within the National HIV Program for 2018 to (a) ensure continuous access to antiretroviral (ARV) treatment for HIV-positive people; and (b) support the implementation of HIV prevention programs among key affected populations (KAPs) such as men who have sex with men (M
Buyers had been warned to diversify the manufacturing base or risk supply interruptions
The Global Fund, one of the main purchasers of generic antiretroviral (ARV) medicines for HIV patients in low- and middle-income countries, has dismissed concerns that the limited number of manufacturers tapped to supply these drugs could result in immediate or future shortages. Fund officials said systems are in place to forecast demand, deal with any supply disruptions and increase production to meet future need.
Number of people on ARVs through programs supported by the Global Fund reaches 9.2 million
In the second half of 2015, through programs supported by The Global Fund, another 641,000 people were put on antiretroviral treatment (ART) for HIV, bringing the total to date to 9.2 million, a 7.5% increase over mid-2015 results and a 14.5% increase over the numbers a year ago.
Number of people on ARVs reaches 8.6 million
In the first half of 2015, through programs supported by The Global Fund, another 500,000 people were put on antiretroviral treatment for HIV, bringing the total to date to 8.6 million, a 7% increase over end-2014 results.